Plasma exposure to insulin glargine and its metabolites M1 and M2 after subcutaneous injection of therapeutic and supratherapeutic doses of glargine in subjects with type 1 diabetes

Diabetes Care

Volumn 35, Issue 12, 2012, Pages 2626-2630

  Bolli, Geremia B ^a   Dahmen, Raphael ^b   Hahn, Annke D ^b   Heise, Tim ^c   Schmidt, Ronald ^b   Becker, Reinhard H A ^b   Eisenblaetter, Tanja ^b  

^a UNIVERSITY OF PERUGIA   (Italy)

^b SANOFI AVENTIS DEUTSCHLAND GMBH   (Germany)

^c Profil Institut fur Stoffwechselforschung   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

A21 GLYCINE DES B30 THREONINE HUMAN INSULIN; A21 GLYCINE HUMAN INSULIN; DRUG METABOLITE; GLUCOSE; INSULIN GLARGINE; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG METABOLISM; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HUMAN; HUMAN CELL; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESPONSE; LIMIT OF QUANTITATION; LIQUID CHROMATOGRAPHY; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; TANDEM MASS SPECTROMETRY;

ADULT; DIABETES MELLITUS, TYPE 1; GLUCOSE CLAMP TECHNIQUE; HUMANS; HYPOGLYCEMIC AGENTS; INJECTIONS, SUBCUTANEOUS; INSULIN, LONG-ACTING; MALE; MIDDLE AGED;

EID: 84869780310     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc12-0270     Document Type: Article

References (27)

1. 2: A new retarding principle based on a natural pro-insulin derived processing intermediate. Diabetes Res Clin Pract 1985;1(Suppl.1):S204
2. Kemmler W, Peterson JD, Steiner DF. Studies on the conversion of proinsulin to insulin. I. Conversion in vitro with trypsin and carboxypeptidase B. J Biol Chem 1971;246:6786-6791
3. Seipke G, Geisen K, Neubauer H-P, Pittius C, Rosskamp R, Schwabe D. New insulin preparations with prolonged action profiles: A21-modified arginine insulins. Diabetologia 1992;35(Suppl.1):A4
4. Steiner DF. Adventures with insulin in the islets of Langerhans. J Biol Chem 2011;286:17399-17421
5. Monti LD, Poma R, Caumo A, et al. Intravenous infusion of diarginylinsulin, an insulin analogue: effects on glucose turn-over and lipid levels in insulin-treated type II diabetic patients. Metabolism 1992;41:540-544
6. Markussen J, Diers I, Hougaard P, et al. Soluble, prolonged-acting insulin derivatives. III. Degree of protraction, crystallizability and chemical stability of insulins substituted in positions A21, B13, B23, B27 and B30. Protein Eng 1988;2:157-166
7. Zeuzem S, Stahl E, Jungmann E, Zoltobrocki M, Schöffling K, Caspary WF. In vitro activity of biosynthetic human diarginylinsulin. Diabetologia 1990;33:65-71 (Pubitemid 20060982)
8. Kurtzhals P, Schäffer L, Sørensen A, et al. Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use. Diabetes 2000;49:999-1005 (Pubitemid 30349423)
9. Kohn WD, Micanovic R, Myers SL, et al. pI-shifted insulin analogs with extended in vivo time action and favorable receptor selectivity. Peptides 2007;28:935-948 (Pubitemid 46349342)
10. Sommerfeld MR, Müller G, Tschank G, et al. In vitro metabolic and mitogenic signaling of insulin glargine and its metabolites. PLoS ONE 2010;5:e9540
11. Kuerzel GU, Shukla U, Scholtz HE, et al. Biotransformation of insulin glargine after subcutaneous injection in healthy subjects. Curr Med Res Opin 2003;19:34-40 (Pubitemid 36378318)
12. Porcellati F, Rossetti P, Busciantella NR, et al. Comparison of pharmacokinetics and dynamics of the long-acting insulin analogs glargine and detemir at steady state in type 1 diabetes: a double-blind, randomized, crossover study. Diabetes Care 2007;30:2447-2452 (Pubitemid 47547770)
13. Lucidi P, Porcellati F, Rossetti P, et al. Pharmacokinetics and pharmacodynamics of therapeutic doses of basal insulins NPH, glargine, and detemir after 1 week of daily administration at bedtime in type 2 diabetic subjects: a randomized cross-over study. Diabetes Care 2011;34:1312-1314
14. Home PD, Fritsche A, Schinzel S, Massi-Benedetti M. Meta-analysis of individual patient data to assess the risk of hypoglycaemia in people with type 2 diabetes using NPH insulin or insulin glargine. Diabetes Obes Metab 2010;12:772-779
15. Bonnesen C, Nelander GM, Hansen BF, et al. Synchronization in G0/G1 enhances the mitogenic response of cells overexpressing the human insulin receptor A isoform to insulin. Cell Biol Toxicol 2010;26:293-307
16. Smith U, Gale EA. Does diabetes therapy influence the risk of cancer? Diabetologia 2009;52:1699-1708
17. Stammberger I, Bube A, Durchfeld-Meyer B, Donaubauer H, Troschau G. Evaluation of the carcinogenic potential of insulin glargine (LANTUS) in rats and mice. Int J Toxicol 2002;21:171-179 (Pubitemid 34803492)
18. Hemkens LG, Grouven U, Bender R, et al. Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study. Diabetologia 2009;52:1732-1744
19. Jonasson JM, Ljung R, Talbäck M, Haglund B, Gudbjörnsdò ttir S, Steineck G. Insulin glargine use and short-term incidence of malignancies-a populationbased follow-up study in Sweden. Diabetologia 2009;52:1745-1754
20. Agin A, Jeandidier N, Gasser F, Grucker D, Sapin R. Glargine blood biotransformation: in vitro appraisal with human insulin immunoassay. Diabetes Metab 2007;33:205-212 (Pubitemid 46863409)
21. Hansen BF, Kurtzhals P, Jensen AB, Dejgaard A, Russell-Jones D. Insulin X10 revisited: a super-mitogenic insulin analogue. Diabetologia 2011;54:2226-2231
22. Heise T, Nosek L, Rønn BB, et al. Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes. Diabetes 2004;53:1614-1620 (Pubitemid 38697678)
23. Thevis M, Thomas A, Delahaut P, Bosseloir A, Schänzer W. Qualitative determination of synthetic analogues of insulin in human plasma by immunoaffinity purification and liquid chromatography-tandem mass spectrometry for doping control purposes. Anal Chem 2005;77:3579-3585 (Pubitemid 40803497)
24. Danne T, Philotheou A, Goldman D, Guo T, Ping L, Johnston P. The Preschool Study: Hypoglycemia assessed by continuous glucose monitoring in 125 children under age 6 with Type 1 diabetes treated with multiple daily insulin injections. Pediatr Diabetes 2011;12(Suppl. 15):122
25. Lucidi P, Porcellati F, Rossetti P, et al. Metabolism of insulin glargine after repeated daily subcutaneous injections in subjects with type 2 diabetes. Diabetes Care 2012;35:2647-2649
26. Sandow J. Growth effects of insulin and insulin analogues. Arch Physiol Biochem 2009;115:72-85
27. Porcellati F, Rossetti P, Ricci NB, et al. Pharmacokinetics and pharmacodynamics of the long-acting insulin analog glargine after 1 week of use compared with its first administration in subjects with type 1 diabetes. Diabetes Care 2007;30:1261-1263 (Pubitemid 46684657)